Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab - Wikidata - thesis-toulmin - TriplyDB

Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab

Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab

http://www.wikidata.org/entity/Q28219257

about

Vascular-endothelial-growth-factor (VEGF) targeting therapies for endocrine refractory or resistant metastatic breast cancer Anti-angiogenic therapies for metastatic colorectal cancer Anticoagulation in combination with antiangiogenesis and chemotherapy for cancer patients: evidence and hypothesis Venous Thromboembolism in Cancer: An Update of Treatment and Prevention in the Era of Newer Anticoagulants Profile of bevacizumab in the treatment of platinum-resistant ovarian cancer: current perspectives Bevacizumab for glioblastoma The Crossroads of Geriatric Cardiology and Cardio-Oncology Venous thromboembolism and lung cancer: a review Targeting angiogenesis in gynecologic cancers Value of bevacizumab in treatment of colorectal cancer: A meta-analysis Cardiac effects of anticancer therapy in the elderly Angiogenic inhibitors for older patients with advanced colorectal cancer: does the age hold the stage?Incidence and risk of sorafenib-induced hypertension: a systematic review and meta-analysis What is the Best Treatment for a Cancer Patient with Thrombosis?Practical management of bevacizumab-related toxicities in glioblastoma Review of systemic therapies for locally advanced and metastatic rectal cancer Engineered antibody Fc variant with selectively enhanced Fc RIIb binding over both Fc RIIaR131 and Fc RIIaH131 The Vascular Endothelial Growth Factor Inhibitors Ranibizumab and Aflibercept Markedly Increase Expression of Atherosclerosis-Associated Inflammatory Mediators on Vascular Endothelial Cells Management of treatment-associated toxicites of anti-angiogenic therapy in patients with brain tumors.Pegaptanib sodium for neovascular age-related macular degeneration: third-year safety results of the VEGF Inhibition Study in Ocular Neovascularisation (VISION) trial.Opportunities and challenges for successful use of bevacizumab in pediatrics.Drug review: Safety and efficacy of bevacizumab for glioblastoma and other brain tumors.Effect of angiogenesis inhibitor bevacizumab on survival in patients with cancer: a meta-analysis of the published literature.Effect of intravitreal anti-vascular endothelial growth factor therapy on the risk of arterial thromboembolic events: a meta-analysis Platelets, petechiae, and preservation of the vascular wall Phase 2 trial of carboplatin, weekly paclitaxel, and biweekly bevacizumab in patients with unresectable stage IV melanoma: a North Central Cancer Treatment Group study, N047A.Drug-induced hematologic syndromes Safety of bevacizumab in patients with advanced cancer: a meta-analysis of randomized controlled trials.Addition of bevacizumab to XELOX induction therapy plus concomitant capecitabine-based chemoradiotherapy in magnetic resonance imaging-defined poor-prognosis locally advanced rectal cancer: the AVACROSS study Combining capecitabine, oxaliplatin, and gemcitabine (XELOXGEM) for colorectal carcinoma patients pretreated with irinotecan: a multicenter phase I/II trial.Treating venous thromboembolism in patients with cancer.Novel adverse events of bevacizumab in the US FDA adverse event reporting system database: a disproportionality analysis.Formation of immune complexes and thrombotic microangiopathy after intravitreal injection of bevacizumab in the primate eye.Concurrent thrombotic thrombocytopenic purpura and immune thrombocytopenic purpura in a patient with metastatic neuroendocrine tumour successfully treated with rituximab-CVP.Understanding, recognizing, and managing toxicities of targeted anticancer therapies.Phase II study of single agent oral vinorelbine as first-line treatment in patients with HER-2 negative metastatic breast cancer.A critical balance: managing coagulation in patients with glioma.Ischemic Heart Disease: Special Considerations in Cardio-Oncology.Effects of an intravitreal bevacizumab injection combined with panretinal photocoagulation on high-risk proliferative diabetic retinopathy Venous thromboembolism prophylaxis and treatment in cancer: a consensus statement of major guidelines panels and call to action.

P2860

Q24202199-58425A9E-FA37-43E3-B91E-49CF59AAE9E9 Q24241813-985EF645-6FFC-4370-B87F-FDA2703A5FA2 Q26740812-AAB94757-F137-4A48-A8BB-5414692A96A0 Q26741697-8618718D-F129-483C-BF67-BF12AE97A7CC Q26751280-C4B10895-5BC3-447A-B874-480EC9BA0591 Q26776307-92013615-36A3-4DF9-ABAD-2E678F56219F Q26778666-A1F1D5FA-9D68-4480-A206-032DBFDD557A Q26784184-55DB5B4D-2C33-4388-8221-2A856C2A942B Q26824766-0011C602-C499-4B3E-A655-35277214FDE0 Q26849789-EEEF8B59-78B4-4F33-9940-0012A3DFB878 Q26863244-5FBE02DB-6093-4D6B-A785-BC8C2BCD6203 Q27002538-FE402928-B3EC-416F-AB11-E5F8C4E5B93F Q27003304-309C3BD0-E542-44B5-889D-12F3B438978E Q27009514-077AEF17-788F-4933-9840-4664731D793E Q27015852-B2B82F82-5F89-4909-8276-2EB030995D77 Q27021105-6A629FB6-ED3F-4505-AF9C-D59532801883 Q27678516-C8B9F144-8933-44E3-98F2-AD66435855A6 Q28550616-41D50913-A9CA-46BE-A717-FF758E57D36B Q30417015-3B3401CC-9179-4759-A06B-1D927DE6AA5F Q30440705-65984B3E-2123-49B7-953B-09D5D3C9291E Q30454883-402C6686-0806-4903-8B1D-75AA905711E6 Q30616602-E71160A0-427E-4078-A28F-4FA3C8E941A1 Q31060162-F6EA59CB-AA23-4110-8036-E7432F96CDCD Q31076710-5A881794-5D7A-453C-96F7-298E3D3EF313 Q33381203-D22E3AFE-A8D2-4827-9BB0-7DBF9310176D Q33382481-0DC9F9AB-8DA5-4107-82FC-7A2E6D3F68D3 Q33387312-13A94033-5850-4DB1-9A01-E445938A06C3 Q33392652-D936EC8B-C76A-4059-B57D-299ACEE808CB Q33394804-EB676924-317D-4465-8925-9E96B978CCFD Q33395485-17367E3B-F935-4DD4-8F76-80F527B8DC80 Q33400564-CC51F709-6B7A-43A2-AC22-3D61CE2A1AD9 Q33401326-902D54BF-BA62-4944-903A-A42B11DD7864 Q33401343-3F310922-2BF2-4557-9F62-10144283DCF5 Q33402349-B68ABE86-7882-4E27-9984-87C935F66F99 Q33408049-9A46AC5D-2E2E-424F-9074-426F34AE1484 Q33408664-254D8BF2-8E31-4A1D-B50F-C48A8C879742 Q33431673-923D0990-D491-4BEE-8673-4838300EDC16 Q33441165-F8355F33-F4FD-479F-A319-582E61CDBBB2 Q33521675-60150548-EAC9-4FCA-86E3-C7549609CD4A Q33561213-A79A54C7-2B2D-45CD-877A-2602571F434C

P2860

Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab

http://www.wikidata.org/entity/Q28219257

description

2007 nî lūn-bûn

@nan

2007 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

name

Arterial thromboembolic events ...... h chemotherapy and bevacizumab

@ast

Arterial thromboembolic events ...... h chemotherapy and bevacizumab

@en

Arterial thromboembolic events ...... h chemotherapy and bevacizumab

@nl

type

label

Arterial thromboembolic events ...... h chemotherapy and bevacizumab

@ast

Arterial thromboembolic events ...... h chemotherapy and bevacizumab

@en

Arterial thromboembolic events ...... h chemotherapy and bevacizumab

@nl

prefLabel

Arterial thromboembolic events ...... h chemotherapy and bevacizumab

@ast

Arterial thromboembolic events ...... h chemotherapy and bevacizumab

@en

Arterial thromboembolic events ...... h chemotherapy and bevacizumab

@nl

P1433

Q28219257-5CC71B74-B585-4F5B-883A-45C91976A5C0

P1476

Q28219257-E741B1CC-3092-4106-8D28-5C81D9218C06

P2093

Q28219257-1BB6ADDB-7CD2-46B6-8454-C2DFD858586A

Q28219257-272BB396-AB0E-4A1B-B44F-1A796CC98472

Q28219257-4CE2A19A-4495-4F7D-8275-A3F6F0AFA660

Q28219257-54F611A6-F431-4CEF-AF82-15B29515519F

Q28219257-5CA9B22F-E558-4E7F-9F8D-A5630662B3E7

Q28219257-84204964-72C1-4C7C-B9C5-7023FE438643

Q28219257-97D0517D-80EF-4914-81A3-88F200A684A7

Q28219257-B2B81759-3489-413A-8C10-76CF996586E7

Q28219257-F02C8AB6-76B4-42A6-882F-7A2BE450DDF9

Q28219257-F04B0D5B-A93F-4A7A-9C40-2C785253ACA6

P2860

Q28219257-1E70AE21-F505-4E01-A691-F5F171593D5A

Q28219257-1FF6DE2D-EBA0-4915-AD75-5532B206D060

Q28219257-2EB2E10B-D619-4D50-9BEE-7EF9A19BAEF1

Q28219257-83AE406E-FADD-4AC3-88CB-C85A558C29C9

Q28219257-8E0BE7D2-7EF1-400F-A612-C32385778C90

Q28219257-977A42C6-A45B-4ACF-91C3-8C3F78CCC910

Q28219257-98DAE700-581C-4AA4-BC52-D0B69229F1ED

Q28219257-9B2CAC2C-FD18-4CE0-AD1E-E74F730539F4

Q28219257-A04C091E-043C-4A89-AD12-088C8CDAC016

Q28219257-A50537D6-CB9E-42A7-86AA-0ED77008E399

P304

Q28219257-88678015-F803-47DF-A573-B0D3391A44F5

P31

Q28219257-0435daa8-cb83-4743-bbad-0e5a05308baf

Q28219257-DB10EB88-D6E4-4445-9CAD-41B24535ABFC

P3181

Q28219257-198FA38C-9B05-4DC7-9179-31E881806BF0

P356

Q28219257-1CF4872D-C74E-4CCB-AB4A-5CD9D1A3A4D8

P407

Q28219257-06021209-FBEE-4AC1-88D2-3AB1C919534A

P433

Q28219257-059412E3-E902-4BE0-800E-003906C34216

P478

Q28219257-F8C7CB66-52D0-4191-B41A-C24FC4139BF8

P577

Q28219257-51F4861A-6B97-42D5-9ECF-3C6A5B6C22AF

P5875

Q28219257-624369E7-2A71-47D9-8FF9-612A664CD8B7

P698

Q28219257-C951C5D1-687B-4957-93BE-29FBD547E2D7

P921

Q28219257-1BBA1FB1-D529-4094-A7CC-06C47A545E6E

Q28219257-37F5C41B-2789-4E77-8349-50BB7EED98B2

Q28219257-81215D1D-A47E-44DB-A68F-E3D4F2CE3856

Q28219257-ADA9B863-EA21-4006-A890-40EBFCC7EB15

P3181

P356

P1433

Journal of the National Cancer Institute

P1476

Arterial thromboembolic events ...... h chemotherapy and bevacizumab

@en

P2093

Emily Bergsland

http://www.w3.org/2001/XMLSchema#string

Eric Holmgren

http://www.w3.org/2001/XMLSchema#string

Fairooz Kabbinavar

http://www.w3.org/2001/XMLSchema#string

Frank A Scappaticci

http://www.w3.org/2001/XMLSchema#string

Hans-Peter Gerber

http://www.w3.org/2001/XMLSchema#string

Herbert Hurwitz

http://www.w3.org/2001/XMLSchema#string

James Ngai

http://www.w3.org/2001/XMLSchema#string

Jamey R Skillings

http://www.w3.org/2001/XMLSchema#string

Jiuzhou Wang

http://www.w3.org/2001/XMLSchema#string

Kathy Miller

http://www.w3.org/2001/XMLSchema#string

P2860

Atherosclerosis — An Inflammatory Disease

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

Oral antiplatelet therapy in cerebrovascular disease, coronary artery disease, and peripheral arterial disease

Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy

Down syndrome critical region protein 1 (DSCR1), a novel VEGF target gene that regulates expression of inflammatory markers on activated endothelial cells

Inflammation in atherosclerosis

Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer.

Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer.

Vascular endothelial growth factor: basic science and clinical progress.

Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial.

P304

1232-9

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

620949

http://www.w3.org/2001/XMLSchema#string

P356

10.1093/JNCI/DJM086

http://www.w3.org/2001/XMLSchema#string

P407

P433

16

http://www.w3.org/2001/XMLSchema#string

P478

99

http://www.w3.org/2001/XMLSchema#string

P577

2007-08-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6152403

http://www.w3.org/2001/XMLSchema#string

P698

17686822

http://www.w3.org/2001/XMLSchema#string

P921

thromboembolism